In silico signaling modeling to understand cancer pathways and treatment responses
暂无分享,去创建一个
Jan Christoph | Maximilian Fuchs | Thomas Dandekar | Meik Kunz | Michael Flentje | Julian Jeromin | Giulia Veronesi | Sarah Nietzer | Gudrun Dandekar | T. Dandekar | G. Veronesi | M. Flentje | Meik Kunz | J. Christoph | M. Fuchs | S. Nietzer | Gudrun Dandekar | J. Jeromin
[1] Thomas Dandekar,et al. The drug-minded protein interaction database (DrumPID) for efficient target analysis and drug development , 2016, Database J. Biol. Databases Curation.
[2] Tzong-Yi Lee,et al. Identification of potential biomarkers related to glioma survival by gene expression profile analysis , 2019, BMC Medical Genomics.
[3] Thomas Dandekar,et al. Convergence behaviour and Control in Non-Linear Biological Networks , 2015, Scientific Reports.
[4] Giovanni De Micheli,et al. Dynamic simulation of regulatory networks using SQUAD , 2007, BMC Bioinformatics.
[5] Tatiana Martins Tilli,et al. Toward precision medicine of breast cancer , 2016, Theoretical Biology and Medical Modelling.
[6] Steven J. M. Jones,et al. Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.
[7] Jongho Kim,et al. An integrated clinical and genomic information system for cancer precision medicine , 2018, BMC Medical Genomics.
[8] Sun Kim,et al. Comprehensive and critical evaluation of individualized pathway activity measurement tools on pan-cancer data , 2018, Briefings Bioinform..
[9] Gary D. Bader,et al. Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..
[10] Wylie Burke,et al. Essential elements of personalized medicine. , 2014, Urologic oncology.
[11] Shingo Iwami,et al. Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs , 2014, Theoretical Biology and Medical Modelling.
[12] Thomas Dandekar,et al. Jimena: efficient computing and system state identification for genetic regulatory networks , 2013, BMC Bioinformatics.
[13] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[14] Laura La Paglia,et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. , 2010, Cancer treatment reviews.
[15] J. Tuszynski,et al. A Computational Strategy to Select Optimized Protein Targets for Drug Development toward the Control of Cancer Diseases , 2015, PloS one.
[16] A. Rosenwald,et al. Germinal Center B Cell-Like (GCB) and Activated B Cell-Like (ABC) Type of Diffuse Large B Cell Lymphoma (DLBCL): Analysis of Molecular Predictors, Signatures, Cell Cycle State and Patient Survival , 2007, Cancer informatics.
[17] Heike Walles,et al. A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds. , 2016, Journal of visualized experiments : JoVE.
[18] Radhakant Padhi,et al. A patient-specific therapeutic approach for tumour cell population extinction and drug toxicity reduction using control systems-based dose-profile design , 2013, Theoretical Biology and Medical Modelling.
[19] Thomas Dandekar,et al. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis , 2008, BMC Cancer.
[20] Laura Tolosi,et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.
[21] Steven J. M. Jones,et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.
[22] Nallasivam Palanisamy,et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.
[23] Heike Walles,et al. Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model , 2013, Molecular oncology.
[24] Heike Walles,et al. A combined tissue‐engineered/in silico signature tool patient stratification in lung cancer , 2018, Molecular oncology.
[25] Roy Kishony,et al. Networks from drug–drug surfaces , 2007, Molecular systems biology.